Cited 0 time in
강직성척추염 환자에서 Infliximab 치료 중발생한 저색소성 균상식육종 1예
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | 김석림 | - |
| dc.contributor.author | 정도선 | - |
| dc.contributor.author | 문윤선 | - |
| dc.contributor.author | 정해봉 | - |
| dc.contributor.author | 김지연 | - |
| dc.date.accessioned | 2022-12-26T21:03:34Z | - |
| dc.date.available | 2022-12-26T21:03:34Z | - |
| dc.date.issued | 2016 | - |
| dc.identifier.issn | 0494-4739 | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/16528 | - |
| dc.format.extent | 2 | - |
| dc.language | 한국어 | - |
| dc.language.iso | KOR | - |
| dc.publisher | 대한피부과학회 | - |
| dc.title | 강직성척추염 환자에서 Infliximab 치료 중발생한 저색소성 균상식육종 1예 | - |
| dc.title.alternative | A Case of Hypopigmented Mycosis Fungoides in a Patient with Ankylosing Spondylitis during Treatment with Infliximab | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.bibliographicCitation | 대한피부과학회지, v.54, no.2, pp 160 - 161 | - |
| dc.citation.title | 대한피부과학회지 | - |
| dc.citation.volume | 54 | - |
| dc.citation.number | 2 | - |
| dc.citation.startPage | 160 | - |
| dc.citation.endPage | 161 | - |
| dc.identifier.kciid | ART002086275 | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.subject.keywordAuthor | Hypopigmented mycosis fungoides | - |
| dc.subject.keywordAuthor | Infliximab | - |
| dc.subject.keywordAuthor | Ankylosing spondylitis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
